Skip to main content

Kirske David's Form 4 filing

Cti Biopharma Corp (CTIC) · filed Sep 20, 2022

Accession no.
0000891293-22-000045
Filed
Sep 20, 2022
Trade date
Jun 30-Sep 16, 2022
Filing delay
82 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $136.0K. It was filed 82 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kirske DavidCIK 0001276750Officer (EVP, Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 30, 2022common stockAGrant or awardAcquired+9,516$2.12+$20,173.9216,913Direct
Sep 16, 2022common stockMOption exerciseAcquired+22,592$0.95+$21,462.439,505Direct
Sep 16, 2022common stockSSaleDisposed−22,592$6.02−$136,003.8416,913Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 16, 2022Common StockMOption exerciseDisposed−22,592$0.00$0467,408Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)